Skip to Content

ASCO GU 2024: A Combination of Cabozantinib and Atezolizumab is Promising for Advanced Prostate Cancer Patients with Poor Prognoses

This article is about the findings of the CONTACT-02 study, highlighting the efficacy of cabozantinib and atezolizumab in treating metastatic castration-resistant prostate cancer (mCRPC) presented at ASCO GU 2024

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top